Back to Search Start Over

Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status

Authors :
Fumihiro, Oshita
Yohei, Miyagi
Takeshi, Honda
Shuji, Murakami
Tetsuro, Kondo
Haruhiro, Saito
Kazumasa, Noda
Tomoyuki, Yokose
Yoichi, Kameda
Yuji, Sakuma
Masato, Obata
Kouzo, Yamada
Source :
Journal of experimental therapeuticsoncology. 8(4)
Publication Year :
2011

Abstract

We prospectively investigated the outcome of personalized second-line treatment based on epidermal growth factor receptor (EGFR) gene status in previously treated patients with advanced non-small cell lung cancer (NSCLC). EGFR gene status was evaluable by LH-mobility shift assay in registered patients. Gefitinib (Gef) treatment was recommended if the patients had EGFR mutation (mEGFR). EGFR gene status was evaluable in 146 patients. Seventy-four of the patients were female, 82 were smokers, and 122 had adenocarcinoma. Overall, 67 patients had mEGFR and received Gef. Forty-nine of 79 patients with wild-type EGFR (wEGFR) received other chemotherapies or radiation but 30 selected best supportive care only as a second-line treatment. Patients with mEGFR survived significantly longer than patients with wEGFR (p0.0001). However, the survival of patients who received other forms of chemotherapy was not different from that of patients who received best supportive care only as a second-line treatment in patients with wEGFR. Examination of the association between overall survival after first-line chemotherapy and prognostic factors using multivariate regression analysis showed that mEGFR and response to first-line chemotherapy were independent factors (p = 0.003 and p = 0.003, respectively). Selection of second-line treatment according to EGFR gene status may be useful for patients with NSCLC.

Details

ISSN :
13594117
Volume :
8
Issue :
4
Database :
OpenAIRE
Journal :
Journal of experimental therapeuticsoncology
Accession number :
edsair.pmid..........a959db52f2b49148baf06f658190ec8b